Therefore, the development of B1R inhibitors is also a potential target for the treatment of sepsis.[34] These results suggest that KLK1 deficiency may activate the MAPK pathway and drive the release of inflammatory factors by upregulating B1R expression, further supporting the role of B1R in amplifying inflammatory responses. This evidence concerns the gene BDKRB1 and Sepsis.